Bibliografisk note

Funding Information:
The SCRATCH database has received financial support from Sanofi Denmark and Pfizer Denmark. Conflicts of interest: HHPL has no conflicts of interest to declare. IV has received a salary from research funding from Sanofi/Re-generon Pharmaceuticals, and honoraria for lecturing from Pfizer. IFR has no conflicts of interest to declare. JE has received research, speaking, and/or consulting support from a variety of companies, including Pfizer, Leo Pharma, Sanofi, Galderma, Novartis, Eli Lilly, AbbVie, AstraZeneca, Saniona, Boehringer Ingelheim, La Roche-Posay and Pierre Fabre Laboratories. LS has been an advisor, investigator and speaker for Abbvie, Eli Lilly, Novatis, Sanofi, Celgene, Leo Pharma, Pfizer, BMS, UCB and Almirall, outside the submitted work. LS reports non-financial support from Abbvie, Sanofi, Janssen and grants from Novartis, Janssen, BMS and Sanofi. KI has received personal fees from Astra Zeneca, Leo Pharma, Sanofi Genzyme and Eli Lilly. GBEJ reports grants and/ or personal fees from Abbvie, Coloplast, Chemocentryx, LEO Pharma, LEO Foundation, Afyx, Incyte, InflaRx, Janssen-Cilag, Novartis, UCB, CSL Behring, Regeneron, Sanofi, Kymera and VielaBio outside the submitted work. CGM has no conflicts of interest to declare. ROB has no conflicts of interest to declare. CB-J has no conflicts of interest to declare. MGD has served on advisory boards with Abbvie, Leo Pharma and Eli Lilly and has received honoraria as a consultant from Eli Lilly TA Advisory board, consultancy, lectures or clinical trials for Sanofi, Eli Lilly, Abbvie and Leo Pharma. MD has received research support and/or honoraria for lecturing, and consulting/advisory board agreements from AbbVie, Eli Lilly, LEO Pharma, La Roche Posay, Incyte, ASLAN Pharmaceuticals, Arena Pharmaceuticals, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme. CV has received honoraria for lectures and boards from Sanofi Genzyme, Eli Lilly, Pfizer, LEO Pharma, Novartis, and Abbvie. He has received research grants from Sanofi Genzyme, Leo Pharma, Novartis and Pfizer. JPT is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, OM Pharma, Aslan Pharmaceuticals, Union Th-erapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron, and Sanofi-Genzyme.

Funding Information:
SCRATCH is a nationwide multi-centre registry aiming to include all Danish patients with AD treated with new systemic medications. The database is a tool for clinicians and patients, that allows easy overview of relevant treatment measures and monitoring of effect and safety. Based on the patient’s signed consent, the data in SCRATCH can be used for research purposes. Funding for the creation and operation of the database has, so far, been based on unrestricted research grants from Sanofi-Genzyme, but the intention is to establish agreement with all interested pharmaceutical companies. ZiteLab ApS, a private software developer, (Frederiksberg, Denmark) is providing the encrypted, web-based database used for collecting and storing data. The research project is approved by the Danish Data Protection Agency (P-2019-746).

Publisher Copyright:
© 2022, Medical Journals/Acta D-V. All rights reserved.